Search research articles
Contact Us
Filters
Showing results (391-400 of 393) with videos related to
Page
of 40
Sort By:
You have reached the last page of results.
This site can display upto 393 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al
P Dubsky, G Curigliano, H J Burstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 26, 2017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, H J Burstein, E P Winer, et al.
Journal of Medical Economics
|
December 12, 2023
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
T Spelman, W L Herring, C Acosta, et al.
Page
of 40
Search research articles
Search
Showing results (391-400 of 393) with videos related to
Sort By:
Page
of 40
You have reached the last page of results.
This site can display upto 393 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 19, 2017
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al
P Dubsky, G Curigliano, H J Burstein, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 26, 2017
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G Curigliano, H J Burstein, E P Winer, et al.
Journal of Medical Economics
|
December 12, 2023
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
T Spelman, W L Herring, C Acosta, et al.
Page
of 40